Business
Issue of Director Shares
Fusion Antibodies plc has issued 308,720 new ordinary shares at 13 pence per share to executive directors Adrian Kinkaid and Richard Buick, satisfying a portion of their bonuses for the year ended March 31, 2025. This issuance, totaling £40,133.60, is part of a larger fundraising effort announced earlier today. The new shares will be admitted to trading on AIM on January 30, 2026, bringing the total voting rights to 125,021,878. Disclaimer*
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\n27 January 2026\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nIssue of Director Shares\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces, further to the notification of the conditional placing and subscription to raise approximately £1.4 million (before expenses) (the \"Fundraise\") released earlier today (the \"Fundraise Announcement\"), the Company has issued 308,720 new ordinary shares of 4p each in the share capital of the Company (\"Ordinary Shares\") to certain executive Directors at a deemed subscription price equal to the Fundraise issue price of 13 pence per new Ordinary Share (the \"Issue Price\") in satisfaction of a portion of their bonuses for the year ended 31 March 2025 (the \"Director Shares\").\n \nAs disclosed in the Company's annual report and accounts for the year ended 31 March 2025 (as announced on 4 September 2025), the remuneration committee recommended, and the board of directors of Fusion (the \"Board\" or the \"Directors\") accepted, a bonus award for Adrian Kinkaid (CEO) and Richard Buick (CSO) each of 20% of their gross salary, against their maximum contractual bonus of 45% and 40% respectively. In recognition that the Company is still controlling costs tightly and cognisant of the cash position, it was agreed that the bonus award be split into two components: 40% cash and the remainder to be satisfied via the issue of new Ordinary Shares once the Company was in an open period.\n \nAs separately indicated in Fundraise Announcement, the Board has now resolved to issue and allot, in aggregate, 308,720 new Ordinary Shares to Adrian Kinkaid (CEO) and Richard Buick (CSO) at a deemed issue price equal to the Issue Price and pursuant to the authorities previously granted at the Company's annual general meeting held on 16 October 2025, as follows:\n \n\n\n\n\nDirector\n\n\nAmount of bonus award to be received in Director Shares\n\n\nNo. of Director Shares issued\n\n\nTotal holding of Ordinary Shares post issue\n\n\nPercentage of enlarged issued share capital1\n\n\n\n\nAdrian Kinkaid\n\n\n£23,846.94\n\n\n183,438\n \n\n\n 1,033,438\n\n\n0.83%\n\n\n\n\...